INTERNATIONAL CONGRESS OF
CancerGenetics
A review of osteoclast inhibitors in primary breast cancer
-
Maryam Mirzalou,1,*
1. Midwifery undergraduate student, Faculty of Medical Sciences, Marand Islamic Azad University, Department of Midwifery, Marand, Iran
- Introduction: Breast cancer is the most common cancer in women worldwide. The prognosis for completely cured early breast cancer is usually very good, in part because of systemic therapies that reduce the risk of recurrence.
- Methods: To identify studies aimed at the role of osteoclast inhibitors in primary breast cancer, this systematic review was conducted in Google Scholar, Science Direct, and PubMed databases based on keywords Breast cancer, Osteoclast inhibitors, and Osteoporosis. After reviewing the summary of the articles and checking the title, the irrelevant articles were removed the full text of the articles was searched and the articles related to the topic were included in the study.
- Results: According to the studies shown, osteoclast inhibitorshave been evaluated as anticancer treatments in an adjunctive setting to improve breast cancer outcomes, treatment with the help of these inhibitors, either for the management of osteoporosis or as an adjuvant treatment, is generally They are well tolerated and reduce the risk of osteoporosis and fractures. Therefore, the prevention of bone loss related to breast caccer, avd the treatment of osteoporosis and osteopenia should be considered first with adequate nutrition (calcium and vitamin D), regular exercise with weight bearing and healthy lifestyle behaviors.
- Conclusion: Osteoporosis is associated with an increased risk of fracture and can be associated with significant morbidity, mortality, disfigurement, loss of self-esteem, as well as health care costs. Thus, systemic therapies used to treat primary breast cancer may be associated with loss of bone mineral density and increased risk of osteoporotic fractures.
- Keywords: breast cancer, osteoclast inhibitors, osteoporosis
